Lexeo Therapeutics, Inc. Operating Income Loss

Quick Answer

Lexeo Therapeutics, Inc. reported Operating Income Loss of -$109.26 million for the year ending 2025.

  • Lexeo Therapeutics, Inc. showed a decrease of -3.3% in Operating Income Loss from 2024 to 2025.
  • This data is from Lexeo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), Lexeo Therapeutics, Inc.'s Operating Income Loss has declined by 80.6%.
  • Historical annual values: Fiscal year 2025: -$109.26 million | Fiscal year 2024: -$105.77 million | Fiscal year 2023: -$68.51 million | Fiscal year 2022: -$60.51 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: